XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 39,915,447 $ 65,813,297
Short-term investments 28,447,097 28,300,232
Accounts receivable from affiliated entity 1,310,237 1,199,056
Prepaid expenses and other current assets 2,221,668 2,517,465
Total current assets 71,894,449 97,830,050
Fixed assets, net 3,347,824 3,659,818
Investments in affiliated entity 2,308,975 1,613,844
Operating lease right-of-use assets 7,741,757 8,113,840
Other assets 1,979,654 1,979,654
Total assets 87,272,659 113,197,206
Current liabilities:    
Accrued clinical trial expenses 1,819,237 2,021,860
Common stock warrant liability 9,542,316 13,255,188
Operating lease liability 2,575,902 2,497,360
Total current liabilities 27,326,880 35,325,584
Operating lease liability, net of current portion 8,695,055 9,367,827
Total liabilities 36,021,935 44,693,411
Stockholders’ equity:    
Preferred stock 0 0
Common stock 36,674 36,099
Additional paid-in capital 1,801,789,329 1,799,362,625
Accumulated deficit (1,749,913,959) (1,730,219,262)
Accumulated other comprehensive loss (661,320) (675,667)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 51,250,724 68,503,795
Total liabilities and stockholders’ equity 87,272,659 113,197,206
Nonrelated Party    
Current liabilities:    
Accounts payable and accrued expenses 12,919,788 16,200,013
Related Party    
Current liabilities:    
Accounts payable and accrued expenses $ 469,637 $ 1,351,163